Suppr超能文献

倍他米松对有早产风险女性的肾上腺抑制作用。

Adrenal suppression induced by betamethasone in women at risk for premature delivery.

作者信息

Helal K J, Gordon M C, Lightner C R, Barth W H

机构信息

Ehrling Bergquist Hospital, Offutt Air Force Base, Bellevue, Nebraska, USA.

出版信息

Obstet Gynecol. 2000 Aug;96(2):287-90. doi: 10.1016/s0029-7844(00)00885-1.

Abstract

OBJECTIVE

To determine whether betamethasone administered to women at risk of preterm delivery causes adrenal suppression.

METHODS

Ten women at risk of preterm delivery had three weekly low-dose (1 microg) ACTH stimulation tests with the first one between 24 and 25 weeks' gestation. Immediately after the first and second ACTH stimulation tests, we gave each woman a 12-mg betamethasone dose intramuscularly and repeated it 24 hours later. The third ACTH stimulation test was 1 week after the second course of betamethasone. Serum cortisol levels were measured before (baseline) and 30 minutes after ACTH administration.

RESULTS

All subjects had normal baseline and stimulated cortisol levels for the first ACTH stimulation test. Mean baseline serum cortisol levels decreased with each ACTH stimulation test, from 25.4 +/- 4.8 microg/dL (before betamethasone) to 4.3 +/- 4.0 microg/dL (1 week after the second course of betamethasone) (P <.001). The mean stimulated cortisol levels also decreased from 33.0 +/- 4.3 microg/dL (before betamethasone) to 11.8 +/- 6.4 microg/dL (1 week after the second course of betamethasone) (P <.001). Compared with initial ACTH stimulation tests, laboratory evidence of adrenal suppression occurred in four patients 1 week after the first course of betamethasone and in seven patients after the second course. No signs or symptoms of Addisonian crisis occurred antepartum or intrapartum.

CONCLUSION

Antenatal administration of betamethasone produced measurable adrenal suppression in women at risk of preterm delivery. The number of women with adrenal suppression increased each week that antenatal betamethasone was repeated. (Obstet Gynecol 2000;96:287-90.)

摘要

目的

确定给有早产风险的女性使用倍他米松是否会导致肾上腺抑制。

方法

10名有早产风险的女性在妊娠24至25周期间进行了三次每周一次的低剂量(1微克)促肾上腺皮质激素(ACTH)刺激试验。在第一次和第二次ACTH刺激试验后,我们立即给每位女性肌肉注射12毫克倍他米松,并在24小时后重复给药。第三次ACTH刺激试验在第二次倍他米松疗程后1周进行。在ACTH给药前(基线)和给药后30分钟测量血清皮质醇水平。

结果

所有受试者在第一次ACTH刺激试验中的基线和刺激后皮质醇水平均正常。随着每次ACTH刺激试验,平均基线血清皮质醇水平下降,从(使用倍他米松前)25.4±4.8微克/分升降至(第二次倍他米松疗程后1周)4.3±4.0微克/分升(P<.001)。平均刺激后皮质醇水平也从(使用倍他米松前)33.0±4.3微克/分升降至(第二次倍他米松疗程后1周)11.8±6.4微克/分升(P<.001)。与最初的ACTH刺激试验相比,4名患者在第一次倍他米松疗程后1周出现肾上腺抑制的实验室证据,7名患者在第二次疗程后出现。产前或产时未出现艾迪生病危象的体征或症状。

结论

产前使用倍他米松在有早产风险的女性中产生了可测量的肾上腺抑制。重复产前使用倍他米松的每周,出现肾上腺抑制的女性数量增加。(《妇产科学》2000年;96:287 - 290)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验